{
    "2020-01-22": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Steven Cohen's Point72 Piles Into Menlo Therapeutics",
                "features": {
                    "keywords": [
                        "Steven Cohen",
                        "Point72",
                        "Menlo Therapeutics"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-20",
                "original_text": "Durham is on a winning streak for new jobs, but will it continue?",
                "features": {
                    "keywords": [
                        "Durham",
                        "winning streak",
                        "new jobs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "economy"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-10",
                "original_text": "Health stocks reverse coronavirus gains as one analyst says the market is overreacting",
                "features": {
                    "keywords": [
                        "Health stocks",
                        "reverse",
                        "coronavirus",
                        "gains",
                        "overreacting"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-12",
                "original_text": "Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",
                "features": {
                    "keywords": [
                        "Stock Analyst Reports",
                        "Pfizer",
                        "Wells Fargo",
                        "SAP"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2022-07-05",
                "original_text": "Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Multiple Myeloma",
                        "FDA",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-01-25",
                "original_text": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
                "features": {
                    "keywords": [
                        "First Trust",
                        "Capital Strength ETF",
                        "FTCS",
                        "Investing Radar"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}